TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31838589

Group type: EXPERIMENTAL
Intervention: PATCH (motivational enhancement intervention)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Stress reduction skills control intervention
Number of subjects: 34
Study: 29389484

Group type: EXPERIMENTAL
Intervention: 8-week spiritual counseling intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Routine education/care (control)
Number of subjects: 42
Study: 25990354

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Number of subjects: 172
Study: 24783925

Group type: EXPERIMENTAL
Intervention: Jianpi suppository
Number of subjects: 120

Group type: COMPARATOR
Intervention: mesalazine
Number of subjects: 120
Study: 23240940

Group type: EXPERIMENTAL
Intervention: Intranasal reduced glutathione (in)GSH
Number of subjects: 70
Study: 20515959

Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented formula
Number of subjects: 107

Group type: COMPARATOR
Intervention: Unsupplemented formula
Number of subjects: 107
Study: 18650154

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Doxorubicin/Cyclophosphamide (AC)
Number of subjects: 76
Study: 17092412

Group type: EXPERIMENTAL
Intervention: Ulinastatin plus thymosin-alpha1 on the base of regular therapy for 1 week
Number of subjects: 70
Study: 12872390

Group type: EXPERIMENTAL
Intervention: Combined medicine (CAL and western medicine)
Number of subjects: 110

Group type: COMPARATOR
Intervention: CAL (composite agastache lotion)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 110
Study: 10693835

Group type: EXPERIMENTAL
Intervention: Prototype gloves (two pairs with different levels of protection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prototype II (laminar glove)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double glove
Number of subjects: 0
Study: 8673643

Group type: EXPERIMENTAL
Intervention: List-making
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-list-making
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: List-making (organized)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: List-making (non-organized)
Number of subjects: 0
Study: 1762283

Group type: EXPERIMENTAL
Intervention: Verapamil (20 patients), daily dose 60‐120 mg, mean 80 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propranolol (20 patients), daily dose 120‐180 mg, mean 140 mg
Number of subjects: 40
Study: 7050868

Group type: EXPERIMENTAL
Intervention: Gentamicin (2.5 mg/kg q6h)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Colistin (1 mg/kg q6h)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall sensitivity patterns
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Incidence of neonatal sepsis
Number of subjects: 100
Study: 4026058

Group type: COMPARATOR
Intervention: HFCWO at 5 Hz with 20 ml tidal volume (Series B)
Number of subjects: 7

Group type: COMPARATOR
Intervention: HFCWO at 5 Hz with 40 ml tidal volume (Series C)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control condition (Series A)
Number of subjects: 7
Study: 31197507

Group type: EXPERIMENTAL
Intervention: Juçara freeze-dried pulp (5 g)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (5 g)
Number of subjects: 27
Study: 28447466

Group type: EXPERIMENTAL
Intervention: Policy and education intervention (personal contacts and theory-based training and materials)
Number of subjects: 98
Study: 27484783

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Remifentanil
Number of subjects: 68
Study: 24314823

Group type: EXPERIMENTAL
Intervention: Regadenoson-stress myocardial CT perfusion (CTP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-photon emission CT (SPECT)
Number of subjects: 0
Study: 21305260

Group type: EXPERIMENTAL
Intervention: Iterative hypothesis testing (IHT) training for 4 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Medical teaching as usual
Number of subjects: 71
Study: 20465558

Group type: EXPERIMENTAL
Intervention: Uterine artery embolisation (UAE)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 96
Study: 19026912

Group type: EXPERIMENTAL
Intervention: Decision-making program
Number of subjects: 0
Study: 15974350

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High intensity exercise group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 12209020

Group type: EXPERIMENTAL
Intervention: Strength Training (ST) program for 9 weeks
Number of subjects: 20
Study: 10609975

Group type: EXPERIMENTAL
Intervention: MTT with contingency contracts using monetary reinforcers targeting abstinence from illicit drug and alcohol use
Number of subjects: 102

Group type: COMPARATOR
Intervention: MTT without contingency contracts targeting abstinence
Number of subjects: 102
Study: 7489456

Group type: EXPERIMENTAL
Intervention: Propofol (120-180 micrograms.kg-1 min-1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Isoflurane (0.8-1.6%)
Number of subjects: 39
Study: 1777375

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31552704

Group type: EXPERIMENTAL
Intervention: 30-min aerobic exercise
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 60-min aerobic exercise
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 45-min aerobic exercise
Number of subjects: 18
Study: 31501887

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/day)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Methotrexate (40 mg/m2/week)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 340

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 340
Study: 29429823

Group type: EXPERIMENTAL
Intervention: Vaginal palpation
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Vaginal palpation with posterior pelvic tilt
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Intravaginal electrical stimulation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (verbal instructions)
Number of subjects: 132
Study: 27029489

Group type: EXPERIMENTAL
Intervention: Coach-based interventions focused on breastfeeding, weight loss, healthy eating, and increased physical activity, predominantly delivered by telephone.
Number of subjects: 740

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 740
Study: 24451954

Group type: EXPERIMENTAL
Intervention: SVV group (using Pulse Indication Continuous Cardiac Output monitoring of SVV, responsiveness defined as SVV ≥12%)
Number of subjects: 58

Group type: COMPARATOR
Intervention: PLR-ΔSV group (using ΔSV before and after PLR as the indicator, responsiveness defined as ΔSV ≥15%)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SVV group
Number of subjects: 58

Group type: COMPARATOR
Intervention: PLR-ΔSV group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 23019074

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study: 20397495

Group type: EXPERIMENTAL
Intervention: Cast gold post‐and‐core group (GG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Heraplat post/cast gold core group (HG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Titanium post/composite core (TC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Titanium post/cast gold core (TG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endodontically treated teeth without posts (ETT, control)
Number of subjects: 50
Study: 17011666

Group type: EXPERIMENTAL
Intervention: Intravenous progesterone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16272751

Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (low dose: 0.03 mg/kg/min for 1 min loading, then 0.01 mg/kg/min for 10 min continuous)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (medium dose: 0.06 mg/kg/min for 1 min loading, then 0.02 mg/kg/min for 10 min continuous)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11579113

Group type: EXPERIMENTAL
Intervention: FEC (fluorouracil, epirubicin, and cyclophosphamide) chemotherapy, six cycles
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control (no adjuvant therapy)
Number of subjects: 248
Study: 11301565

Group type: EXPERIMENTAL
Intervention: Nitrazepam (5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7523538

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Therapeutic interventions
Number of subjects: 36
Study: 2964861

Group type: EXPERIMENTAL
Intervention: Progestogens
Number of subjects: 429

Group type: COMPARATOR
Intervention: Control
Number of subjects: 429
Study: 28786330

Group type: COMPARATOR
Intervention: Extensive on-site monitoring
Number of subjects: 1618

Group type: EXPERIMENTAL
Intervention: Risk-adapted monitoring
Number of subjects: 1618
Study: 26486322

Group type: EXPERIMENTAL
Intervention: Tacker technique for peritoneal closure
Number of subjects: 64

Group type: COMPARATOR
Intervention: Suture technique for peritoneal closure
Number of subjects: 64
Study: 23386054

Group type: EXPERIMENTAL
Intervention: Low-fidelity training
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-fidelity training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (didactic instruction)
Number of subjects: 18
Study: 21369739

Group type: EXPERIMENTAL
Intervention: LYMPHA technique (lymphatic-venous anastomoses)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No preventive surgical approach (control group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: LYMPHA technique
Number of subjects: 46
Study: 18835681

Group type: EXPERIMENTAL
Intervention: Strengths-based case management intervention
Number of subjects: 245

Group type: COMPARATOR
Intervention: Passive referral (control)
Number of subjects: 245
Study: 17097217

Group type: EXPERIMENTAL
Intervention: Tolterodine extended release (ER) 4mg QD
Number of subjects: 1698

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1698
Study: 15562908

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11676157

Group type: EXPERIMENTAL
Intervention: Cervical collar therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no therapeutic intervention)
Number of subjects: 38
Study: 9089428

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily for a maximum of 10 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Lisinopril (10 mg once daily for a maximum of 10 weeks)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Metolazone (1 mg once daily for a maximum of 10 weeks)
Number of subjects: 84
Study: 8404433

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg three times a day)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 3544188

Group type: EXPERIMENTAL
Intervention: Carbenoxolone/antacid/alginate preparation (Pyrogastrone)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Antacid/alginate alone (Control)
Number of subjects: 59
Study: 30894206

Group type: EXPERIMENTAL
Intervention: Mother's bed incline at 45°
Number of subjects: 5866

Group type: COMPARATOR
Intervention: Mother's bed incline at 15°
Number of subjects: 5866
Study: 28853967

Group type: EXPERIMENTAL
Intervention: Monopolar RF device treatment (4 once-a-week sessions)
Number of subjects: 19
Study: 27039080

Group type: EXPERIMENTAL
Intervention: Rosuvastatin at 20 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ezetimibe at 10 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Colestimide at 3.62 g/day
Number of subjects: 16
Study: 24642620

Group type: EXPERIMENTAL
Intervention: Carboplatin + Decitabine (5-aza-2'-deoxycytidine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carboplatin alone
Number of subjects: 30
Study: 22000272

Group type: EXPERIMENTAL
Intervention: Glaucoma education (video scripted at a 4th, 7th, or 10th grade level)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 127
Study: 20055764

Group type: EXPERIMENTAL
Intervention: CobraPLA
Number of subjects: 60

Group type: COMPARATOR
Intervention: LMA
Number of subjects: 60
Study: 18793577

Group type: EXPERIMENTAL
Intervention: Ritalin LA(R) under fasted condition
Number of subjects: 28

Group type: COMPARATOR
Intervention: Medikinet retard under fasted condition
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ritalin LA(R) under fed condition
Number of subjects: 28

Group type: COMPARATOR
Intervention: Medikinet retard under fed condition
Number of subjects: 28
Study: 16310021

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo intervention (Control Group; CG)
Number of subjects: 31
Study: 12742488

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 161

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 161
Study: 10233878

Group type: EXPERIMENTAL
Intervention: metronidazole and ciprofloxacin
Number of subjects: 134

Group type: COMPARATOR
Intervention: ciprofloxacin alone
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: combined decontamination medication
Number of subjects: 134
Study: 8912751

Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation at 25 ppm
Number of subjects: 7
Study: 8373975

Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CS) using CoSPAN catheter
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-shot spinal anesthesia (SS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 3762248

Group type: EXPERIMENTAL
Intervention: Persistently high levels of use of services (1974-79)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower levels of use of services (1974-79)
Number of subjects: 0
Study: 31608733

Group type: EXPERIMENTAL
Intervention: Docetaxel monotherapy
Number of subjects: 10633
Study: 29698250

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (5 mg/kg)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 27154174

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg co-administered with vismodegib 150 mg QD for 7 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg co-administered with vismodegib 150 mg QD for 7 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg co-administered with vismodegib 150 mg QD for 7 days
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control arm: Vismodegib 150 mg QD for 7 days
Number of subjects: 66
Study: 23402387

Group type: EXPERIMENTAL
Intervention: Calcium resonium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not on treatment)
Number of subjects: 100
Study: 21561544

Group type: EXPERIMENTAL
Intervention: Buttonhole cannulation technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rope ladder rotation technique
Number of subjects: 70
Study: 19527323

Group type: EXPERIMENTAL
Intervention: aliskiren/valsartan/HCTZ
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: aliskiren/HCTZ
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: valsartan/HCTZ
Number of subjects: 641

Group type: COMPARATOR
Intervention: HCTZ alone
Number of subjects: 641
Study: 17701949

Group type: EXPERIMENTAL
Intervention: Function-preserving surgery (modified facelift incision, greater auricular nerve preservation, partial parotidectomy, coverage with parotid fascia)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 101
Study: 15319760

Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Treatment (SMT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-Spinal Manipulation Treatment (N-SMT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 11448383

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication with anterior hiatal repair
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication with posterior hiatal repair
Number of subjects: 102
Study: 9234829

Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg orally daily for 1 week
Number of subjects: 9
Study: 8270925

Group type: EXPERIMENTAL
Intervention: Vigabatrin (1 g twice daily for six weeks, followed by 1.5 g twice daily for a further six weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vigabatrin (continued use after the trial)
Number of subjects: 24
Study: 3100510

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 30532268

Group type: EXPERIMENTAL
Intervention: rSh28GST/Alhydrogel (Bilhvax)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Alhydrogel (control group)
Number of subjects: 250
Study: 27710915

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 25048345

Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) findings including heart rate, Q waves, and Cornell voltage‐duration product
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Combination of ECG variables
Number of subjects: 1473
Study: 22203755

Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg twice per day
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg twice per day
Number of subjects: 97

Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m² intravenously every 28 days
Number of subjects: 97
Study: 20729336

Group type: EXPERIMENTAL
Intervention: Priming loneliness in Studies 1-3
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Daily assessments of positive affect (PA) and relatedness needs satisfaction (RNS) in Study 4
Number of subjects: 420
Study: 18611273

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus a platinum compound
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine plus irinotecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine plus 5-fluorouracil
Number of subjects: 0
Study: 16013010

Group type: EXPERIMENTAL
Intervention: lipo-prostaglandin E1 (PGE1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 42
Study: 12972964

Group type: EXPERIMENTAL
Intervention: Adhesion barrier membrane wrapped around the limbs of the ileostomy, closure at three weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with no barrier membrane, closure after more than six weeks.
Number of subjects: 0
Study: 10378707

Group type: EXPERIMENTAL
Intervention: Samarium-153 particulate hydroxyapatite (Sm-153 PHYP) synovectomy
Number of subjects: 10
Study: 8863239

Group type: EXPERIMENTAL
Intervention: Conservative, delayed surgery after intensive chemotherapy with or without radiotherapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Additional chemotherapy and late exenteration, prostatectomy, or biopsy for patients with relapse or residual disease
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Gross primary excision, local radiotherapy, and vincristine and actinomycin therapy for group IIA tumors
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (IRS‐II)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Patients with metastatic disease (group IV)
Number of subjects: 44
Study: 1651360

Group type: EXPERIMENTAL
Intervention: CMV-specific intravenous immunoglobulin (IVIG) 200 mg/kg on days 8 and 6 before transplant, the day after transplant, weekly for the first month, and then every 2 weeks to complete 10 doses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 60
Study: 7075915

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 507

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Initial test 2-h blood glucose value
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Males and obese subjects
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Fasting and 2-h glucose values
Number of subjects: 507
Study: 30730425

Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Classic physiotherapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (nonback pain participants)
Number of subjects: 65
Study: 28110153

Group type: EXPERIMENTAL
Intervention: Efficient technique model (1 model)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Inefficient technique models (4 models)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (equal number of inefficient and efficient models)
Number of subjects: 202
Study: 24655598

Group type: EXPERIMENTAL
Intervention: 40 mg atomoxetine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: No-drug control
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Higher structural frontostriatal connectivity
Number of subjects: 21
Study: 24507823

Group type: EXPERIMENTAL
Intervention: 100 ml wine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 200 ml wine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 300 ml wine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cut-off value of 8.84 μg/mg creatinine
Number of subjects: 21
Study: 22853848

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/Amlodipine 5 mg (I150/A5)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Amlodipine 5 mg (A5)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/Amlodipine 10 mg (I150/A10)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Amlodipine 10 mg (A10)
Number of subjects: 287